Atara Biotherapeutics (ATRA) Operating Leases (2019 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Operating Leases came in at $9.1 million in Q1 2026, down 66.02% YoY from $26.7 million in Q1 2025, and down 2.9% on a QoQ basis from $9.3 million in Q4 2025.
Atara Biotherapeutics (ATRA) Operating Leases (2019 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 8 years of Operating Leases data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Operating Leases fell 66.02% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 66.02% YoY) and the FY2025 annual result came in at $9.3 million, down 68.75% from the prior year.
- Operating Leases fell to $9.1 million in Q1 2026, from $9.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $64.0 million in Q2 2022 to a low of $9.1 million in Q1 2026.
- A 5-year average of $36.7 million and a median of $38.7 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases soared 425.36% — and 2025, when it tumbled 68.75%.
- Tracing ATRA's Operating Leases over 5 years: stood at $58.1 million in 2022, then dropped by 21.31% to $45.7 million in 2023, then plunged by 34.53% to $29.9 million in 2024, then plunged by 68.75% to $9.3 million in 2025, then retreated by 2.9% to $9.1 million in 2026.
- The last three Operating Leases figures came in at $9.1 million (Q1 2026), $9.3 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - |
| 10 | Atara Biotherapeutics | 142.96 Mn | 126.41 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.78 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | 9.35 Mn |
| Sep 30, 2025 | 15.01 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Mar 31, 2025 | 26.71 Mn |
| Dec 31, 2024 | 29.91 Mn |
| Sep 30, 2024 | 35.24 Mn |
| Jun 30, 2024 | 38.70 Mn |
| Mar 31, 2024 | 42.20 Mn |
| Dec 31, 2023 | 45.69 Mn |
| Sep 30, 2023 | 48.51 Mn |
| Jun 30, 2023 | 51.75 Mn |
| Mar 31, 2023 | 54.92 Mn |
| Dec 31, 2022 | 58.06 Mn |
| Sep 30, 2022 | 61.07 Mn |
| Jun 30, 2022 | 64.00 Mn |
| Mar 31, 2022 | 17.45 Mn |
| Dec 31, 2021 | 25.52 Mn |
| Sep 30, 2021 | 24.57 Mn |